Edition:
United Kingdom

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

25.02EUR
4:35pm BST
Change (% chg)

€-0.06 (-0.24%)
Prev Close
€25.08
Open
€25.08
Day's High
€25.36
Day's Low
€24.92
Volume
102,712
Avg. Vol
240,081
52-wk High
€32.98
52-wk Low
€20.11

Chart for

About

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €769.50
Shares Outstanding(Mil.): 31.17
Dividend: --
Yield (%): --

Financials

  GNFT.PA Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.49 -- --
ROI: -38.89 1.58 14.38
ROE: -41.34 2.41 16.07

BRIEF-Genfit announces milestone for RESOLVE-IT Phase 3 Trial

* Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort

11 Apr 2018

BRIEF-Genfit FY Net Loss Widens To 58.6 Million Euros

* 2017: A YEAR OF VERY SIGNIFICANT REINFORCEMENT OF THE CASH POSITION (€274M AT 12.31.2017), WITH ALL PROGRAMS IN THE COMPANY'S PIPELINE MOVING FORWARD

13 Mar 2018

BRIEF-Genfit: Official Launch Of NASH Pediatric Program In US

* REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA

23 Jan 2018

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR

22 Nov 2017

Earnings vs. Estimates